De SK - Search Results

1

Ureteric wall thickness as a novel predictor for failed retrograde ureteric stent placement.

Dean NS, Albers P, Senthilselvan A, Bain A, Mancuso M, McLarty R, Schuler T, Wollin TA, De SK. Dean NS, et al. Among authors: de sk. Can Urol Assoc J. 2024 Oct;18(10):349-352. doi: 10.5489/cuaj.8845. Can Urol Assoc J. 2024. PMID: 39037511 Free PMC article.

2

Arsenic Induced Oxidative Neural-Damages in Rat are Mitigated by Tea-Leave Extract via MMPs and AChE Inactivation, Shown by Molecular Docking and in Vitro Studies with Pure Theaflavin and AChE.

Medda N, Maiti S, Acharyya N, Samanta T, Banerjee A, De SK, Ghosh TK, Maiti S. Medda N, et al. Among authors: de sk. Cell Biochem Biophys. 2024 Sep;82(3):2567-2583. doi: 10.1007/s12013-024-01369-8. Epub 2024 Jun 28. Cell Biochem Biophys. 2024. PMID: 38943009

3

Are renal stone protocol computed tomography reports giving us enough information?

Bayley C, Hogarth DB, McLarty R, De SK, Schuler T. Bayley C, et al. Among authors: de sk. Can Urol Assoc J. 2024 Oct;18(10):310-315. doi: 10.5489/cuaj.8739. Can Urol Assoc J. 2024. PMID: 38896479 Free PMC article.

4

Leniolisib: a novel treatment for activated phosphoinositide-3 kinase delta syndrome.

De SK. De SK. Front Pharmacol. 2024 Feb 12;15:1337436. doi: 10.3389/fphar.2024.1337436. eCollection 2024. Front Pharmacol. 2024. PMID: 38410131 Free PMC article.

5

Extensive Pulmonary Cryptococcosis as a Presentation in an Immunocompetent Young Male: A Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Finding.

Chauhan P, Singh V, De SK, Gupta M, Nath A, Ora M. Chauhan P, et al. Among authors: de sk. Indian J Nucl Med. 2023 Oct-Dec;38(4):394-395. doi: 10.4103/ijnm.ijnm_47_23. Epub 2023 Dec 20. Indian J Nucl Med. 2023. PMID: 38390534 Free PMC article.

6

Pirtobrutinib: First Non-covalent Tyrosine Kinase Inhibitor for Treating Relapsed or Refractory Mantle Cell Lymphoma in Adults.

De SK. De SK. Curr Med Chem. 2024;31(30):4757-4762. doi: 10.2174/0109298673251030231004052822. Curr Med Chem. 2024. PMID: 37818564 Review.

7

New Pyrrolopyrimidines as LRRK2 Inhibitors for Treating Parkinson's Disease.

De SK. De SK. Curr Med Chem. 2024;31(33):5477-5480. doi: 10.2174/0929867331666230821101247. Curr Med Chem. 2024. PMID: 37605404

8

Novel Pyrazino[2,3-b] Pyrazines as mTOR Kinase Inhibitors for Treating Cancer and other Diseases.

De SK. De SK. Curr Med Chem. 2024;31(34):5657-5659. doi: 10.2174/0929867331666230726112328. Curr Med Chem. 2024. PMID: 37493157 Review.

9

Novel Pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazoles as Protein Kinase C Inhibitors for Treating Diseases.

De SK. De SK. Curr Med Chem. 2023 May 31. doi: 10.2174/0929867330666230531164754. Online ahead of print. Curr Med Chem. 2023. PMID: 37259937

10

Pyrazolo[4,3-H]quinazolines as Cyclin-dependent Kinase Inhibitors for Treating Cancer.

De SK. De SK. Curr Med Chem. 2023 May 25. doi: 10.2174/0929867330666230525160458. Online ahead of print. Curr Med Chem. 2023. PMID: 37231730

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

198 results

Search Page

Filters